You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

Rethinking Risk Stratification for Nonischemic HF: What Do the Latest Data Suggest?

  • Authors: A. John Camm, MD; Manesh R. Patel, MD; J. Rod Gimbel, MD
  • CME / ABIM MOC Released: 4/18/2017
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 4/18/2018
Start Activity


Target Audience and Goal Statement

This activity is intended for cardiologists, emergency department physicians, critical care specialists, and all clinicians interested in risk stratification for nonischemic HF.

The goal of this activity is to improve strategies to use a WCD to risk stratify patients with heart failure who would benefit from an ICD.

Upon completion of this activity, participants will have increased knowledge regarding the:

  • Latest data on the role of implantable cardioverter-defibrillators (ICDs) in patients with nonischemic heart failure (HF)
  • Risk stratification strategies to identify patients with HF who would benefit from an ICD
  • Effective strategies for using a wearable cardioverter-defibrillator (WCD) to risk stratify patients with HF who would benefit from an ICD


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Moderator

  • A. John Camm, MD

    Professor of Clinical Cardiology, St. George's University of London, Cardiovascular and Cell Sciences Research Institute London, United Kingdom

    Disclosures

    Disclosure: A. John Camm, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc.; Boston Scientific; Bristol-Myers Squibb Company; Daiichi Sankyo, Inc.; Lilly; Medtronic, Inc.; Menarini Diagnostics; Mitsubishi Tanabe Pharma Corporation; Novartis Pharmaceuticals Corporation; Richmond Pharmacology; SERVIER; St. Jude Medical
    Served as a speaker or a member of a speakers bureau for: Pfizer Inc
    Other: DSMB BIO|GUARD MI Biotronik; DSMB CASTLE-AF Biotronik; DSMB St. Jude Medical

    Dr Camm does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Camm does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Panelists

  • J. Rod Gimbel, MD

    Clinical Cardiac Electrophysiologist, Columbia-St. Mary's Hospital System, Milwaukee, Wisconsin

    Disclosures

    Disclosure: J. Rod Gimbel, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Medtronic, Inc.

    Dr Gimbel does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Gimbel does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

  • Manesh R. Patel, MD

    Chief of Cardiology, Associate Professor, Division of Cardiology, Duke Clinical Research Institute, Durham, North Carolina

    Disclosures

    Disclosure: Manesh R. Patel, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Bayer HealthCare Pharmaceuticals; Genzyme Corporation; Janssen Pharmaceuticals, Inc.
    Received grants for clinical research from: AstraZeneca Pharmaceuticals LP; Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; MAQUET, Inc.; Tryton Medical, Inc.

    Dr Patel does not intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Patel does not intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editors

  • Joy P. Marko, MS, APN-C, CCMEP

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Joy P. Marko, MS, APN-C, CCMEP, has disclosed no relevant financial relationships.

  • Katherine L. DeYoung, PhD

    Medical Writer, Savannah, GA

    Disclosures

    Disclosure: Katherine L. DeYoung, PhD, has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Amy Bernard, MS, BSN, RN-BC

    Lead Nurse Planner, Medscape, LLC

    Disclosures

    Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.


Accreditation Statements



In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

Rethinking Risk Stratification for Nonischemic HF: What Do the Latest Data Suggest?

Authors: A. John Camm, MD; Manesh R. Patel, MD; J. Rod Gimbel, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME / ABIM MOC Released: 4/18/2017

Valid for credit through: 4/18/2018

processing....

  • Print